Pulnovo reports two U.S. procedures in the PULSE-LHD trial. The estimated 750-participant IDE study uses a sham control; no ...
Put this method on a file you are actually deciding. Witfire Elite provides pharmaceutical due diligence services built on the method used in every brief published here: every figure traced to a ...
AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved that early safety, brain exposure and a novel mechanism can still move a small Nordic biotech into a multibillion-dollar ...
Bright scientific image illustrating eplontersen TTR silencing in transthyretin amyloid cardiomyopathy, cardiac amyloid burden and the challenge of adding a silencer to stabilizer therapy. HELIOS-B ...
No efficacy concern. No safety concern. A launch Sobi valued at SEK 4–6 billion, stopped by a third-party facility. And it was the second of three manufacturing-driven rejections the FDA issued in ...
Bright biotech illustration for Unicycive’s OLC CRL, showing nanoparticle formulation, manufacturing control strategy, FDA quality risk and CDMO execution failure. No safety concern. No efficacy ...
RP1 showed a roughly one-in-three response rate, durable activity, and a favorable safety profile in anti-PD-1-failed advanced melanoma. The FDA rejected it anyway — not because the drug had obviously ...
The Witfire Elite Pharma News aims to publish accurate, responsible, and useful pharma and healthcare industry coverage. If an article contains a factual error, outdated information, incorrect company ...
The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed study. Read against the registry it is the sixth attempt to take a rare-disease drug into a large ...
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell. Viridian entered a $1.9 billion market at price parity with a shorter infusion course and a broader label. Two months earlier, ...
A bright clinical concept image showing the stabilizer ceiling in amyloidosis, where modern background therapy reduces the detectable benefit of add-on drugs. HELIOS-B cleared its endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results